Mineralys Therapeutics Inc Quick Ratio (MLYS) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Mineralys Therapeutics Inc   (NASDAQ: MLYS)

Mineralys Therapeutics Inc 's Quick Ratio

MLYS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 1.91 below Mineralys Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 11 other companies have achieved higher Quick Ratio than Mineralys Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 124, from total ranking in the second quarter 2026 at 461.

Explain Quick Ratio?
How much Cash & cash equivalents MLYS´s has?
What are MLYS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MLYS/financial-strength
https://api.csimarket.com/api/v1/companies/MLYS/fundamentals
https://api.csimarket.com/api/v1/companies/MLYS/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
MLYS Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 125.66 %
Y / Y Cash & cash equivalent Change -53.46 %
Quick Ratio MRQ 1.91
MLYS's Total Ranking # 124
Seq. Current Liabilities Change 174.73 %
Seq. Cash & cash equivalent Change -84.97 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 12
Healthcare Sector # 17
Overall Market # 124


Quick Ratio Statistics
High Average Low
34.87 10.12 2.39
(Jun 30 2026)   (Jun 30 2024)




Financial Statements
Mineralys Therapeutics Inc 's Current Liabilities $ 53 Millions Visit MLYS's Balance sheet
Mineralys Therapeutics Inc 's Cash & cash equivalent $ 101 Millions Visit MLYS's Balance sheet
Source of MLYS's Sales Visit MLYS's Sales by Geography


Cumulative Mineralys Therapeutics Inc 's Quick Ratio

MLYS's Quick Ratio for the trailling 12 Months

MLYS Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 38.66 %
Y / Y Cash & cash equivalent TTM Growth 77.23 %
Quick Ratio TTM 10.38
Total Ranking TTM # 3337
Seq. Current Liabilities TTM Growth 40.67 %
Seq. Cash & cash equivalent TTM Growth -9.88 %

Quick ratio ranking by company, industry and sector >> Back to MLYS Financial Strength Comparisons >> Go to Compare MLYS Quick Ratio to its Competitors

  News about Mineralys Therapeutics Inc Quick Ratio

Mineralys Therapeutics Propels Innovative Treatment for Hypertension and Chronic Kidney Disease with $120 Million Private Placement Financing.

Mineralys Therapeutics Secures $120 Million in Private Placement Financing, Advancing Promising Treatment for Hypertension and Chronic Kidney Disease
RADNOR, Pa., Feb. 08, 2024 Mineralys Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing innovative medicines to tackle hypertension, chronic kidney disease (CKD), and other conditions driven by abnormally elevated aldosterone, has recently announced a significant milestone. The company has successfully entered into a securities purchase agreement with institutional accredited investors for a private placement financing. This financing round is expected to generate approximately $120 million in gross proceeds, which will be instrumental in further advancing Mineralys Therapeutics groundbreaking research and development efforts.
Mineralys Therapeutics aims to address critical unmet medical needs by developing cutting-edge therapies that target aldosterone, an essential hormone associated with regulating blood pressure and fluid balance in the body. Abnormal elevation of aldosterone levels has been linked to hypertension, CKD, and other related diseases, presenting a significant challenge in current treatment approaches. With this private placement financing, Mineralys Therapeutics intends to accelerate the development of its promising drug candidates and propel them towards clinical trials and regulatory approval.

On the trailing twelve months basis Due to in Current Liabilities in the Q3 2026 to $53.08 millions, cumulative Quick Ratio decreased to 10.38 above the MLYS average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 416 other companies have achieved higher Quick Ratio than Mineralys Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 3337, from total ranking during the twelve months ending second quarter 2026 at 3461.

Explain Quick Ratio?
How much Cash & cash equivalents MLYS´s has?
What are MLYS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 417
Healthcare Sector # 848
Within the Market # 3337


trailing twelve months Quick Ratio Statistics
High Average Low
9.19 6.55 3.41
(Dec 31 2023)   (Sep 30 2024)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Aquestive Therapeutics Inc   5.22 $ 90.349  Millions$ 17.299  Millions
Sionna Therapeutics Inc   5.11 $ 83.878  Millions$ 16.420  Millions
Gain Therapeutics inc  4.94 $ 11.698  Millions$ 2.369  Millions
Rani Therapeutics Holdings Inc   4.91 $ 45.288  Millions$ 9.223  Millions
Abeona Therapeutics Inc   4.87 $ 134.941  Millions$ 27.707  Millions
Shattuck Labs Inc   4.84 $ 61.758  Millions$ 12.758  Millions
Mereo Biopharma Group Plc  4.75 $ 26.097  Millions$ 5.494  Millions
Spruce Biosciences Inc   4.69 $ 87.691  Millions$ 18.710  Millions
Septerna Inc   4.56 $ 478.601  Millions$ 104.863  Millions
Atossa Therapeutics Inc   4.37 $ 20.574  Millions$ 4.709  Millions
Neurogene Inc   4.35 $ 78.942  Millions$ 18.163  Millions
Entrada Therapeutics Inc   4.34 $ 112.302  Millions$ 25.863  Millions
Gyre Therapeutics Inc   4.34 $ 86.190  Millions$ 19.874  Millions
Cellectar Biosciences Inc   4.24 $ 24.582  Millions$ 5.798  Millions
Foghorn Therapeutics Inc   4.19 $ 156.222  Millions$ 37.315  Millions
Calcimedica Inc   4.12 $ 13.768  Millions$ 3.339  Millions
Revelation Biosciences Inc   3.92 $ 9.122  Millions$ 2.328  Millions
Tonix Pharmaceuticals Holding Corp   3.87 $ 162.793  Millions$ 42.026  Millions
Lyell Immunopharma Inc   3.83 $ 177.106  Millions$ 46.271  Millions
Rapport Therapeutics Inc   3.68 $ 74.754  Millions$ 20.302  Millions
Seaport Therapeutics Inc   3.60 $ 61.552  Millions$ 17.106  Millions
Xilio Therapeutics Inc   3.47 $ 122.182  Millions$ 35.258  Millions
Corbus Pharmaceuticals Holdings Inc   3.30 $ 115.337  Millions$ 34.967  Millions
Maia Biotechnology Inc   3.30 $ 21.339  Millions$ 6.474  Millions
Cytokinetics Incorporated  3.20 $ 1,130.021  Millions$ 353.419  Millions
Elicio Therapeutics Inc   3.11 $ 30.900  Millions$ 9.930  Millions
Harmony Biosciences Holdings inc   3.02 $ 771.138  Millions$ 254.981  Millions
Phio Pharmaceuticals Corp  2.96 $ 10.609  Millions$ 3.583  Millions
Zevra Therapeutics Inc   2.95 $ 122.148  Millions$ 41.369  Millions
Nextcure Inc   2.95 $ 8.728  Millions$ 2.960  Millions

Date modified: 2026-11-05T05:19:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.